The combination of low intensity ultrasound with microbubbles results in acoustic streaming effects which cause microclot lysis. The use of a thrombolytic agent, recombinant tissue plasminogen activators (rtPA), further increases microclot lysis.
“Microclots are increasingly recognized as a key factor in persistent long COVID symptoms that can significantly impact quality of life, such as fatigue, breathlessness, and cognitive dysfunction, yet treatment options remain limited,” said Dr. Soren Konecky, Chief Technology Officer at Openwater. “These results show that our portable LIFU device could provide a safer way to restore blood flow and potentially relieve chronic inflammation.”
Ad Statistics
Times Displayed: 49030
Times Visited: 1528 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
“Today’s treatments for microclots are often invasive and carry significant risks for patients,” added Aaron Timm, Openwater’s CEO. “Our study demonstrates that low-intensity focused ultrasound can safely and effectively break down these persistent clots, without the need for surgery or clot-dissolving drugs. The results of this study offer hope for a safer, non-invasive solution to help people suffering from long COVID symptoms.”
As the healthcare community searches for effective long COVID therapies, Openwater’s platform could offer a promising, affordable, and drug-free solution suitable for clinics, urgent care centers, and even home use. Looking ahead, Openwater is committed to making this technology widely accessible, with a goal to reduce the device’s cost to $500 within the next several years. Ongoing research and development, including AI-driven enhancements, aim to further improve precision, ease-of-use, and patient outcomes.
About Openwater
Openwater is an AI-driven medical technology company founded by Dr. Mary Lou Jepsen to make hospital-grade care universally accessible. Backed by notable supporters including Khosla Ventures, Plum Alley, BOLD Capital Partners, Vitalik Buterin, Esther Dyson, and Peter Gabriel, Openwater employs open-source development and consumer electronics manufacturing to lower the cost and speed the delivery of non-invasive medical devices. The company collaborates with leading institutions worldwide to research, validate, and distribute these technologies, aiming to reach patients across borders and income levels.
Back to HCB News
